{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004558","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.694543+00:00","generated_at":"2026-05-28T03:39:57.543191+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Beam Therapeutics: $850.7M cash, pipeline progress, 2025 catalysts detailed","bullets":["Preliminary cash, equivalents and marketable securities of $850.7M as of Dec 31, 2024; runway now into 2027 including BEAM-101 commercial readiness.","More than 40 adult SCD patients enrolled in BEACON trial; Beam expects to dose 30 patients and present updated data by mid-2025.","Initial Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency expected in first half 2025.","BEAM-301 Phase 1/2 trial in GSD1a: first site active, dosing to commence in early 2025.","ESCAPE nongenotoxic conditioning IND-enabling studies underway; BEAM-103 healthy volunteer study expected by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004558","json":"https://secwatch.observer/filing/0000950170-25-004558.json","markdown":"https://secwatch.observer/filing/0000950170-25-004558.md","text":"https://secwatch.observer/filing/0000950170-25-004558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025004558/0000950170-25-004558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017025004558/beam-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:39:57.543191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}